Ori CAR 005
Alternative Names: Ori-CAR-005Latest Information Update: 23 Jun 2022
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 10 Jun 2022 Ori CAR 005 is available for licensing as of 10 Jun 2022. https://www.oricell.com/en/
- 10 Jun 2022 Preclinical trials in Gastrointestinal cancer in China (Parenteral) (OriCell Therapeutics pipeline, June 2022)
- 10 Jun 2022 Preclinical trials in Pancreatic cancer in China (Parenteral) (OriCell Therapeutics pipeline, June 2022)